| Budget Amount *help |
¥45,500,000 (Direct Cost: ¥35,000,000、Indirect Cost: ¥10,500,000)
Fiscal Year 2022: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
Fiscal Year 2021: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
Fiscal Year 2020: ¥13,260,000 (Direct Cost: ¥10,200,000、Indirect Cost: ¥3,060,000)
Fiscal Year 2019: ¥14,560,000 (Direct Cost: ¥11,200,000、Indirect Cost: ¥3,360,000)
|
|---|
| Outline of Final Research Achievements |
The goal of this study is to identify important genes in embedding and progression of acute myeloid leukemia (AML) in vivo. Functional genomic screening using shRNAs and sgRNAs was performed in bone marrow transplantation experiments with mouse AML cells, and Rnf20 was identified as a responsible gene for bone marrow engraftment of AML. Also, the study clarified that Bcl11a suppresses the transcriptional activity of PU.1 in malignant transformation of AML, and identified Asb2 as an important Bcl11a arget gene. Moreover, the study revealed the role of Trib1 in Hoxa9-associated super-enhancer regulation to induce up-regulation of Erg.
|
